U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07008976) titled 'Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer' on May 30.
Brief Summary: This study adopted a randomized, open-label, positive drug-controlled, multi-center trial design. The primary endpoint was PFS evaluated by the Independent Review Committee (IRC). Eligible subjects were randomly assigned in a 1:1 ratio to receive either TQB2102 for injection or trastuzumab emtansine for injection.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Metastatic Breast Cancer
Intervention:
DRUG: TQB2102 Injection
TQB2102 Injection is a Human Epidermal...